Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Clinical trial NCT05771480 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05771480
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-16
- Primary completion
- 2025-10-02
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.